Staphylococcal exopolysaccharides inhibit lymphocyte proliferative responses by activation of monocyte prostaglandin production.
The glycocalyx (exopolysaccharides) of Staphylococcus epidermidis has been reported to inhibit a variety of host defense mechanisms. We have examined the inhibitory effects of glycocalyx on the proliferation of human peripheral blood mononuclear cells (PBMC) and the mechanism of this inhibition. Glycocalyx isolated and partially purified under endotoxin-free conditions from defined liquid medium cultures of S. epidermidis and Staphylococcus lugdunensis inhibited the proliferative response of PBMC when added to cultures at 10 to 100 micrograms/ml. Glycocalyx-mediated inhibition of phytohemagglutinin-stimulated proliferation of PBMC required the presence of plastic-adherent peripheral blood monocytes. Culture supernatants of monocytes stimulated with glycocalyx contained a soluble factor that inhibited the proliferation of monocyte-depleted PBMC. This soluble inhibitory factor was not produced in the absence of glycocalyx or in the presence of both glycocalyx and indomethacin. Analysis of the supernatants of cultures of adherent monocytes revealed that glycocalyx from S. epidermidis and from S. lugdunensis could activate monocyte production of prostaglandin E2 (PGE2), human interleukin-1, and tumor necrosis factor alpha. The addition of purified PGE2, at the same levels of PGE2 (greater than or equal to 10(-9) M) generated in the monocyte cultures, to PBMC cultures resulted in a similar inhibition of proliferative responses. It is concluded that, contrary to previous suggestions, the bacterial glycocalyx does not have a direct inhibitory effect on T lymphocytes. However, it does appear that glycocalyx from coagulase-negative staphylococci can activate monocyte PGE2 production and that it is this activity that in turn contributes to the inhibition of T-cell proliferation.
Stout
R D
RD
Department of Microbiology, James H. Quillen College of Medicine, East Tennessee State University, Johnson City 37614-0579.
Ferguson
K P
KP
Li
Y N
YN
Lambe
D W
DW
D000328:Adult; D015232:Dinoprostone / Q000096:biosynthesis*; D006023:Glycoproteins / Q000633:toxicity*; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000187:drug effects*; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism*; D010835:Phytohemagglutinins; D011134:Polysaccharides / Q000633:toxicity*; D013210:Staphylococcus / Q000378:metabolism*; D013601:T-Lymphocytes / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D006023:Glycoproteins; D007375:Interleukin-1; D010835:Phytohemagglutinins; D011134:Polysaccharides; D014409:Tumor Necrosis Factor-alpha; D015232:Dinoprostone